|
1
|
Xu Y, Shi QL, Ma H, et al: High thymidine
kinase 1 (TK1) expression is a predictor of poor survival in
patients with pT1 of lung adenocarcinoma. Tumour Biol. 33:475–483.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rauhala A, Rantalaiho V, Almqvist A and
Putkonen M: Serum thymidine kinase in the monitoring of lymphoma
patients. Duodecim. 111:428–434. 1995.(In Finnish).
|
|
3
|
Sampi K, Takagi T, Sakai C, Kuraishi Y and
Ishige K: Clinical application of thymidine kinase activity in
patients with acute non-lymphocytic leukemia. Gan To Kagaku Ryoho.
18:69–73. 1991.(In Japanese).
|
|
4
|
Shintani M, Urano M, Takakuwa Y, et al:
Immunohistochemical characterization of pyrimidine synthetic
enzymes, thymidine kinase-1 and thymidylate synthase in various
types of cancer. Oncol Rep. 23:1345–1350. 2010.
|
|
5
|
Mao Y, Wu J, Wang N, et al: A comparative
study: immunohistochemical detection of cytosolic thymidine kinase
and proliferating cell nuclear antigen in breast cancer. Cancer
Invest. 20:922–931. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aufderklamm S, Hennenlotter J, Todenhoefer
T, et al: Xpa-210: a new proliferation marker determines locally
advanced prostate cancer and is a predictor of biochemical
recurrence. World J Urol. 30:547–552. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stalhandske P, Wang L, Westberg S, et al:
Homogeneous assay for real-time and simultaneous detection of
thymidine kinase 1 and deoxycytidine kinase activities. Anal
Biochem. 432:155–164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He Q, Zhang P, Zou L, et al: Concentration
of thymidine kinase 1 in serum (S-TK1) is a more sensitive
proliferation marker in human solid tumors than its activity. Oncol
Rep. 14:1013–1019. 2005.PubMed/NCBI
|
|
9
|
Li Z, Wang Y, Ma J, et al: Transient
increase in serum thymidine kinase 1 within one week after surgery
of patients with carcinoma. Anticancer Res. 30:1295–1299.
2010.PubMed/NCBI
|
|
10
|
Aufderklamm S, Todenhofer T, Gakis G, et
al: Thymidine kinase and cancer monitoring. Cancer Lett. 316:6–10.
2012. View Article : Google Scholar
|
|
11
|
Sakamoto S, Hirai H, Taga H, et al:
Thymidine kinase and alpha-fetoprotein as biochemical markers of
hepatocarcinogenesis induced by
3′-methyl-4-dimethylaminoazobenzene treatment in rats.
Carcinogenesis. 11:145–150. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo P, He E, Eriksson S, et al: Thymidine
kinase activity in serum of renal cell carcinoma patients is a
useful prognostic marker. Eur J Cancer Prev. 18:220–224. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O’Neill KL, Zhang F, Li H, Fuja DG and
Murray BK: Thymidine kinase 1-a prognostic and diagnostic indicator
in ALL and AML patients. Leukemia. 21:560–563. 2007.PubMed/NCBI
|
|
14
|
Zhang J, Jia Q, Zou S, et al: Thymidine
kinase 1: A proliferation marker for determining prognosis and
monitoring the surgical outcome of primary bladder carcinoma
patients. Oncol Rep. 15:455–461. 2006.
|
|
15
|
Gronowitz JS and Kallander CF: Optimized
assay for thymidine kinase and its application to the detection of
antibodies against herpes simplex virus type 1- and 2-induced
thymidine kinase. Infect Immun. 29:425–434. 1980.PubMed/NCBI
|
|
16
|
Kemik O, Kemik AS, Purisa S and Tuzun S:
Serum thymidine kinase is associated with gastric adenocarcinoma.
Bratisl Lek Listy. 112:510–511. 2011.PubMed/NCBI
|
|
17
|
Rivkina A, Vitols G, Murovska M and
Lejniece S: Identifying the stage of new CLL patients using TK,
ZAP-70, CD38 levels. Exp Oncol. 33:99–103. 2011.PubMed/NCBI
|
|
18
|
Barth RF, Yang W, Wu G, et al: Thymidine
kinase 1 as a molecular target for boron neutron capture therapy of
brain tumors. Proc Natl Acad Sci USA. 105:17493–17497. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu W, Cao X, Miao KR, et al: Serum
thymidine kinase 1 concentration in Chinese patients with chronic
lymphocytic leukemia and its correlation with other prognostic
factors. Int J Hematol. 90:205–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Konoplev SN, Fritsche HA, O’Brien S, et
al: High serum thymidine kinase 1 level predicts poorer survival in
patients with chronic lymphocytic leukemia. Am J Clin Pathol.
134:472–477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Euler HP, Ohrvik AB and Eriksson SK: A
non-radiometric method for measuring serum thymidine kinase
activity in malignant lymphoma in dogs. Res Vet Sci. 80:17–24.
2006.PubMed/NCBI
|
|
22
|
Magnac C, Porcher R, Davi F, et al:
Predictive value of serum thymidine kinase level for Ig-V
mutational status in B-CLL. Leukemia. 17:133–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brockenbrough JS, Morihara JK, Hawes SE,
et al: Thymidine kinase 1 and thymidine phosphorylase expression in
non-small- cell lung carcinoma in relation to angiogenesis and
proliferation. J Histochem Cytochem. 57:1087–1097. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Raman G, Gaylor JM, Rao M, et al: Quality
of reporting in systematic reviews of implantable medical devices
[Internet]. Rockville (MD): Agency for Healthcare Research and
Quality (US). Report No.: 12(13)-EHC116-EF. 2012
|
|
25
|
Li F, Tie R, Chang K, et al: Does risk for
ovarian malignancy algorithm excel human epididymis protein 4 and
CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC
Cancer. 12:2582012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang J, Xv Z, Wu X and Li K: Potential
diagnostic value of serum p53 antibody for detecting esophageal
cancer: a meta-analysis. PLoS One. 7:e528962012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang XW, Xiong YH, Zen XQ, Lin HB and Liu
QY: Diagnostic accuracy of ultrasonograph guided fine-needle
aspiration cytologic in staging of axillary lymph node metastasis
in breast cancer patients: a meta-analysis. Asian Pac J Cancer
Prev. 13:5517–5523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Galhardo AP, da Costa Leite C, Gebrim EM,
et al: The correlation of research diagnostic criteria for
temporomandibular disorders and magnetic resonance imaging: a study
of diagnostic accuracy. Oral Surg Oral Med Oral Pathol Oral Radiol.
115:277–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Egger M, Smith GD and Phillips AN:
Meta-analysis: principles and procedures. BMJ. 315:1533–1537. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Egger M and Smith GD: Meta-analysis.
Potentials and promise. BMJ. 315:1371–1374. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Egger M, Davey SG, Schneider M and Minder
C: Bias in meta-analysis detected by a simple, graphical test. BMJ.
315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Walther EK, Dahlmann N and Gorgulla HT:
Tumor markers in the diagnosis and follow-up of head and neck
cancer: role of CEA, CA 19-9, SCC, TK, and dTTPase. Head Neck.
15:230–235. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu XH, Zhang YM, Shu XH, et al: Serum
thymidine kinase 1 reflects the progression of pre-malignant and
malignant tumors during therapy. Mol Med Report. 1:705–711.
2008.PubMed/NCBI
|
|
34
|
Nisman B, Yutkin V, Nechushtan H, et al:
Circulating tumor m2 pyruvate kinase and thymidine kinase 1 are
potential predictors for disease recurrence in renal cell carcinoma
after nephrectomy. Urology. 76:513.e1–513.e6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Z, Wang Y, He J, et al: Serological
thymidine kinase 1 is a prognostic factor in oesophageal, cardial
and lung carcinomas. Eur J Cancer Prev. 19:313–318. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nisman B, Allweis T, Kaduri L, et al:
Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark.
7:65–72. 2010.PubMed/NCBI
|
|
37
|
Carlsson L, Larsson A and Lindman H:
Elevated levels of thymidine kinase 1 peptide in serum from
patients with breast cancer. Ups J Med Sci. 114:116–120. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McKenna PG, O’Neill KL, Abram WP and
Hannigan BM: Thymidine kinase activities in mononuclear leukocytes
and serum from breast cancer patients. Br J Cancer. 57:619–622.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alegre MM, Robison RA and O’Neill KL:
Thymidine kinase 1 upregulation is an early event in breast tumor
formation. J Oncol. 2012:5756472012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Romain S, Spyratos F, Descotes F, et al:
Prognostic of DNA-synthesizing enzyme activities (thymidine kinase
and thymidylate synthase) in 908 T1-NT2, N0-N1, M0 breast cancers:
a retrospective multicenter study. Int J Cancer. 87:860–868. 2000.
View Article : Google Scholar
|
|
41
|
Di Raimondo F, Giustolisi R, Lerner S, et
al: Retrospective study of the prognostic role of serum thymidine
kinase level in CLL patients with active disease treated with
fludarabine. Ann Oncol. 12:621–625. 2001.PubMed/NCBI
|
|
42
|
Vrzalova J, Prazakova M, Novotny Z, et al:
Test of ovarian cancer multiplex xMAP technology panel. Anticancer
Res. 29:573–576. 2009.PubMed/NCBI
|
|
43
|
Votava T, Topolcan O, Holubec LJ, et al:
Changes of serum thymidine kinase in children with acute leukemia.
Anticancer Res. 27:1925–1928. 2007.PubMed/NCBI
|
|
44
|
Svobodova S, Topolcan O, Holubec L, et al:
Prognostic importance of thymidine kinase in colorectal and breast
cancer. Anticancer Res. 27:1907–1909. 2007.PubMed/NCBI
|
|
45
|
Swets JA: Measuring the accuracy of
diagnostic systems. Science. 240:1285–1293. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dinnes J, Deeks J, Kirby J and Roderick P:
A methodological review of how heterogeneity has been examined in
systematic reviews of diagnostic test accuracy. Health Technol
Assess. 9:1–113. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hwang Y, Wang B and Bushman FD:
Molluscum contagiosum virus topoisomerase: purification,
activities, and response to inhibitors. J Virol. 72:3401–3406.
1998.PubMed/NCBI
|
